Evidence map›Paper›PMID 36394151›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2023

Nano-Theranostic Modality for Visualization of the Placenta and Photo-Hyperthermia for Potential Management of Ectopic Pregnancy.

Abraham S Moses, Leena Kadam, Anna St Lorenz, Maureen K Baldwin, Terry Morgan, Jessica Hebert, Youngrong Park, Hyelim Lee, Ananiya A Demessie, Tetiana Korzun and 5 more

Open access · greenAbstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Abraham S MosesDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR, 97201, USA.
Leena KadamDepartment of Obstetrics and Gynecology, School of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
Anna St LorenzDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR, 97201, USA.
Maureen K BaldwinDepartment of Obstetrics and Gynecology, School of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
Terry MorganDepartment of Pathology and Laboratory Medicine, School of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
Jessica HebertDepartment of Obstetrics and Gynecology, School of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
Youngrong ParkDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR, 97201, USA.
Hyelim LeeDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR, 97201, USA.
Ananiya A DemessieDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR, 97201, USA.
Tetiana KorzunDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR, 97201, USA.ORCID 0000-0002-5871-2778
Babak MamnoonDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR, 97201, USA.
Adam W G AlaniDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR, 97201, USA.
Oleh TaratulaDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR, 97201, USA.ORCID 0000-0002-6227-9110
Leslie MyattDepartment of Obstetrics and Gynecology, School of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.
Olena R TaratulaDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR, 97201, USA.
Oregon State University · USOregon Health & Science University · US

Funding

Oregon Clinical and Translational Research Institute KL2 SupplementKL2TR002370 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Catherine Lee Hough · 2017 to 2026
$10.1M
OHSU Women's Reproductive Health Research K12 ProgramK12HD085809 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Aaron B Caughey · 2015 to 2026
$4.0M
Novel Nanomedicine-Based Therapeutic Approach For Treatment of Cancer CachexiaR37CA234006 · NCI · OREGON STATE UNIVERSITY · PI TARATULA, OLEH · 2019 to 2025
$3.2M
Intravascular Delivery of Nanoclusters for Treatment of Deep-Seated Cancers with Magnetic HyperthermiaR01CA237569 · NCI · OREGON STATE UNIVERSITY · PI TARATULA, OLEH · 2020 to 2024
$2.7M
Development of magnetic hyperthermia for the systemic treatment of endometriosisR01HD101450 · NICHD · OREGON STATE UNIVERSITY · PI SLAYDEN, OV D, TARATULA, OLEH · 2021 to 2024
$2.4M
Nanocarriers for placenta-specific delivery of imaging and therapeutic agentsR03TR004020 · NCATS · OREGON STATE UNIVERSITY · PI TARATULA, OLENA · 2022 to 2023
$141k
NCATS NIH HHS KL2 TR002370NCATS NIH HHS R03 TR004020NCI NIH HHS R01 CA237569NCI NIH HHS R37 CA234006NICHD NIH HHS K12 HD085809NICHD NIH HHS R01 HD101450
6 · The paper itself

Abstract

Ectopic pregnancy (EP) is the leading cause of maternity-related death in the first trimester of pregnancy. Approximately 98% of ectopic implantations occur in the fallopian tube, and expedient management is crucial for preventing hemorrhage and maternal death in the event of tubal rupture. Current ultrasound strategies misdiagnose EP in up to 40% of cases, and the failure rate of methotrexate treatment for confirmed EP exceeds 10%. Here the first theranostic strategy for potential management of EP is reported using a near-infrared naphthalocyanine dye encapsulated within polymeric nanoparticles. These nanoparticles preferentially accumulate in the developing murine placenta within 24 h following systemic administration, and enable visualization of implantation sites at various gestational stages via fluorescence and photoacoustic imaging. These nanoparticles do not traverse the placental barrier to the fetus or impact fetal development. However, excitation of nanoparticles localized in specific placentas with focused NIR light generates heat (>43 °C) sufficient for disruption of placental function, resulting in the demise of targeted fetuses with no effect on adjacent fetuses. This novel approach would enable diagnostic confirmation of EP when current imaging strategies are unsuccessful, and elimination of EP could subsequently be achieved using the same nano-agent to generate localized hyperthermia resulting in targeted placental impairment.

Indexed as

Hyperthermia, InducedPregnancy, EctopicAnimalsFallopian TubesFemaleHumansMicePlacentaPregnancyUltrasonographyectopic pregnancynanoparticlesNIR imagingphotoacoustic imagingphoto-hyperthermia (PHT)placenta visualization

Identifiers

PMID36394151
PMCPMC9839489
OpenAlexW4309243902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.